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The porcine bioprosthesis has been the prosthetic valve 
of choice at Henry Ford Hospital since October 1971. By 
1979, 23 cases of degeneration had been seen, and the 
rate seven years after implantation was 16%. Now, with a 
ten-year follow-up, there are 41 degenerated valves. 
After seven years, the percent free of degeneration is 
88%, (SE of2%> [standard error]); at eight years, 82% (SE of 
2.9%,); at nine years, 80% fSf 0^.4%); and af ten years, 
the percent free of degeneration is 69% fSf of 6.5%,). 
There was no difference in degeneration between men 
and women, between aortic or mitral position, or 
between the valves which were or were not rinsed in 
antibiotics. The incidence of degeneration was signifi-
cantly greater in patients under 35 years ofage. Contrary 
to our expectations, the number of valves removed for 
degeneration has not increased linearly, although the 
number at risk has continued to rise. In 1977, we 
removed four valves for degeneration; in 1978, eight 
valves; /'n 7979,77 valves; in 1980, five valves; and in 1981, 
ten valves. The duration of implantation for degener-
ated valves has increased from 56 months (SD [standard 
deviation] ofli months) in 1977-78 to 77 months (SD of 
19 months) in 1981. Analysis of cohorts from 1972,1973, 
1974, all now followed for seven years, reveals that at 
seven years the percent free of degeneration for 1972 is 
88% (Sf of 4.4%,); for 1973,83% (Sf of4.8%o); and for 1974, 
95% (Sf of2.6%). Although a difference is suggested, it is 
not yet statistically significant (p = .48) due to the small 
number of valves degenerating. The incidence of por-
cine bioprosthetic degeneration appears to be decreas-
ing, possibly because valves manufactured later in the 
series are more durable. 
I n the search for an ideal tissue heart valve prosthesis, 
the porcine aortic bioprosthesis was a natural progres-
sion f rom the aortic allografts. Allografts, using tissue 
f rom the same species, were used enthusiastically, as first 
reported by Duran in 1962 (1), because they improved 
the hemodynamics and decreased thrombogenicity when 
compared to mechanical protheses. Problems of avail-
ability, sterility, and durability next led to the use of 
strut-mounted fascia lata valves (2). At a workshop on 
tissue heart vaives in 1969, allogeneic fascia lata valves 
seemed to have the greatest promise, while xenogenic 
valves, using tissue f rom different species, were rele-
gated toa minor position (3). However, the poor durabil-
ity and high infection rate of the fascia lata valves (4) led 
to the use of xenogenic valves. The aortic valve o f the pig 
and calf seemed to be the best choices based on the 
relative vascularity and similarity of their physical prop-
erties to those of human valves (3). O'Brien (5) showed 
that these valves were satisfactory for clinical use. The 
one drawback of the porcine aortic valve is that its right 
coronary leaflet contains an inflexible septal shelf of 
myocardi um that reduces the active orif ice area and 
introduces variability in its performance as a bioprosthe-
sis (6). 
Originally, xenogenic valves were treated with mercuri-
al salts to sterilize them and destroy their antigenicity. 
However, these valves failed in a short t ime because of 
collagen degeneration and inflammatory cell infiltration 
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(7). O'Brien (8) and lonescu (9) proposed using formalin-
treated valves, but these valves deteriorated rapidly due 
to a reversible binding of formalin with valve protein, 
which led to a reversal of collagen cross-linking in vivo. 
The resultant loss of fixation led to mechanical failure of 
the disrupted collagen and an immunologic reaction 
with the unbound, antigenically active proteins (10). 
Glutaraldehyde, used as a tanning agent by the shoe 
industry because it produces stable collagen cross-
l inking while maintaining flexibil i ty, was used by Car-
pentier (3). Al though the initial results reported in 1969 
were favorable, it was not until an oxidizing step with 
methylperiodate was eliminated that buffered glutaral-
dehyde, in its present concentrations, could be used to 
preserve collagen both in vivo and in vitro (11). 
Valves were treated in buffered glutaraldehyde and then 
mounted on dacron or tef lon-covered stents using the 
two-suture line technique that Barrat-Boyes developed 
foraorticallografts(12). Reis' introduction of the flexible 
stent (13) was an important step since it markedly 
decreased mechanical stress on the tissue and resulted 
in less fatigue. Consequently, by 1970, a porcine biopros-
thetic valve was being produced that was sterile and 
readily available in all sizes. This prosthesis had low 
antigenicity and projected durabil ity greater than either 
allografts or formalin-treated valves. 
The porcine xenograft bioprosthesis has been the pros-
thetic valve of choice at Henry Ford Hospital since 
October 1971. The valve has performed well hemody-
namically and has a low incidence of thromboembolism. 
As with all tissue valves, the main concern is its durabi l-
ity. The fol lowing is a report on the natural history of the 
porcine bioprosthesis, with a maximum fol low-up of ten 
years, four months. 
Materials and Methods 
All patients who have had a porcine bioprosthetic valve 
inserted are fol lowed by yearly visit or letter as close as 
possible to the anniversary of implantation. All patients 
were accounted for in 1981; fo l low-up was 100%. 
Spontaneous degeneration o f the porcine bioprosthesis 
is indicated clinically by valve incompetence or stenosis 
and confirmed by degeneration of changes on gross or 
histological examination o f the explanted valve. Degen-
eration was not judged to be spontaneous in the pres-
ence of clinical, bacteriological, or histological evidence 
of endocarditis. 
Actuarial curves for valve survival wi thout degeneration 
were constructed according to the method of Berkson 
and Gage (14). Confidence limits were determined as 
described by Irwin (15). Groups were compared by the 
chi-square test wi th matrix inversion (16). 
Results 
Forty-one instances of spontaneous valve degeneration 
have occurred in a fo l low-up period of up to 124 
months. Sixteen patients have been fol lowed longer 
than ten years. The survival of valves wi thout degenera-
t ion, calculated according to the life table method (14), is 
plotted in Fig. 1. The earliest degenerated valve occurred 
at 14 months, the next at 40 months. The percent valve 
survival wi thout degeneration was as follows: at five 
years, 96% (SE of 1.0%); at six years, 93% (SE of 1.5%); at 
seven years, 88% (SE of 2.0%); at eight years, 82% (SE of 
2.9%); at nine years, 80% (SE of 3.4%); and at ten years, 
69% (SE of 6.5%). 
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Fig.1 
Survival of valves w i thou t degenerat ion w i th longest fo l l ow-up at 10 
years. 
There was no significant difference (p = 0.30) between 
male patients (362 valves) and female patients (382 
valves). There were 284 aortic, 427 mitral, and 33 tricus-
pid valves at risk. Valve survival wi thout degeneration 
indicated no significant difference (p = 0.77) between 
aortic and mitral valves. 
Survival wi thout degeneration was compared for five 
age groups: up to 20 years, 21 to 25 years, 26 to 30 years, 
31 to 35 years, and older than 35 years. Degeneration was 
shown to be similar for all age groups under 35 years. 
However, the difference between those under 35 and 
those over35 was significant (p = .005), as shown in Fig. 2. 
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Fig. 2 
Survival of valves w i thou t degenerat ion for those patients under 35 
and those over 35 years of age. The di f ference was significant (p = .005). 
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Fig. 3 
Survival of valves w i thou t degenerat ion for patients under 35 and over 
35 years of age and for posi t ion. For bo th aortic and mitral positions, 
patients under 35 yearsold had a poorer response than patients over 35 
years o ld . 
There was no significant difference (p = 0.69) when valve 
position was analyzed by sex of the patient. However, 
when valve position and the age groups under 35 and 
over 35 years were analyzed, those over 35 (Fig. 3) had a 
significantly greater degeneration free percentage for 
both aortic and mitral positions (p = 0.03). 
Before October 1974, the porcine bioprosthetic valves 
were immersed in a solution containing 1 gm neomycin 
and 10,000 units of bacitracin in 100 ml of saline, as 
outl ined in the manufacturer's instructions (17). These 
instructions were revised in October 1974, with the 
warning that neomycin and bacitracin "w i l l cause a 
chemical change tending to make the leaflets stiff" (8). 
Subsequently, in our institution, valves were rinsed only 
in lactate Ringer's solution. To determine whether anti-
biotic rinsing might play a part in degeneration, we 
compared the survival of valves implanted before October 
15, 1974 ("early") to that of valves implanted subse-
quently that had not undergoneantibioticrinsing("late"). 
At six years, the survival for early valves was 93% (SE of 
1.9%) and for late valves it was 94% (SE of 2.5%) (p = 0.83). 
In 1980, we reported eight years of experience with 
porcine bioprosthetic valves (19). During the previous 
year,11 valves had been removed for degeneration, and 
we expected the number of valves requiring removal for 
degeneration to increase linearly with the increasing 
number of valves at risk and increasing length of implan-
tation. However, as seen in Fig. 4, this has not been the 
case. In 1977, four valves were removed for spontaneous 
degeneration, eight in 1978,11 in 1979; in 1980 only five 
valves were removed for degeneration, in 1981, ten, and 
thus far in 1982, only two. The total number of valves at 
risk has increased each year; and in October 1981, there 
were 557. Similarly, the duration of implantation until 
degeneration has lengthened. Whereas in 1977 and1978 
it was 56 months (SD of 11.8 months), the t ime increased 
in 1979 (71 months,SD of 14.4 months),1980 (79 months, 
SD of 15.7 months), 1981 (77 months, SD of 19 months), 
and in 1982 (113 months, SD of 1.4 months). Thus, 
degeneration is occurring less frequently than was pre-
dicted in 1980. 
To evaluate further this evidence that valves implanted 
early in the series behaved differently f rom those 
implanted later, we analyzed valve cohorts by year of 
NUMBER OF VALVES 
AT RISK ( S Df I . t N [ fJA Tf • 
79 •80 1981 
Fig. 4 
Degenerated Valves Removed: 1971-1981. 
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implantation. Excluding 1971 when oniy 15 porcine 
valves were inserted (none of which degenerated), three 
cohorts with at least seven years' fo l low-up are available 
for analysis. At seven years, the percentage of valves free 
of degeneration is as follows: 1972, 88% (SE of 4.4%); 
1973,83% (SE of 4.8%); 1974,95% (SE of 2.6%). Although 
the difference between these three cohorts is not statis-
tically significant due to the small numbers of degener-
ated valves, the evidence suggests that valves implanted 
in 1974 are more durable than those implanted in 1972 
and 1973 (Fig. 5). However, this is true only if the cohorts 
in the three years are equally matched for age, which is 
the one risk factor for degeneration. The mean age for 
the three years was similar (1972, 47.4 years, SD of 13.7 
years; 1973,47.3 years, SD of 13.9 years; 1974,46.5 years, 
SD of 13.1 years), but the distribution among patients 35 
years and younger was dissimilar. In 1972,15 of 73 (20%) 
were 35 years and younger; in 1973,15 of 78 (19%); and in 
1974, 5 of 80 (8%). This difference is important if the 
patients with degenerated valves in 1972 and 1973 were 
35 years or younger. Of the 13 degenerated valves in the 
1972 cohort , 9 (69%) were in patients under 35 years; in 
1973,4 of 14 (29%); and in 1974,2 of 4 (50%). The differ-
ence in the rate of degeneration between the 1972 and 
the 1974 cohort may be due to the larger number of 
younger patients in the 1972 group. However, this does 
not explain why the 1973 group has a greater incidence 
of degeneration than the 1974 group, since most degen-
erated valves occurred in patients over 35 years old. 
Incidence of degeneration in 1982 is less than predicted 
in 1980. Only further fo l low-up wil l show if this trend is 
real and give clues to the reasons. 
PERCENT VALVES FREE OF DEGENERATION 
AT 7 YEARS 
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Fig. 5 
Survival of valves w i thou t degenerat ion for the cohorts f rom 1972, 
1973,1974, all of which have had at least seven years' fo l low-up. 
Discussion 
The limitation of a tissue valve is its durabil ity. Tissue 
failure has led to the abandonment of homografts (20), 
fascia lata valves (2), and xenografts fixed with mercurials 
and formalin (7,10). The first xenobioprostheses treated 
with the buffered glutaraldehyde were inserted in 1969 
(21), and more t ime is required to evaluate Carpentier's 
prediction of 80% tissue survival for ten years (22). 
The glutaraldehyde-treated procine bioprosthesis has 
been subjected in vitro to durability evaluation by accel-
erated fatigue testing. Although these tests show tears 
near the commissures (23,24) and collagen disruption 
due to compression force at the base of the leaflet (25), it 
is diff icult to apply the results to clinical situations. The 
mode of failure may be similar to that seen clinically, but 
it is diff icult to predict whether the failure wil l occur 
after two (23) or 12 (25) years. We agree with Rainer that 
in vitro studies do not allow us to predict the fate of the 
tissue valves in a clinical setting (26). A numberof reports 
describe the spontaneous degeneration or primary 
tissue failure of porcine bioprosthetic valves (26-35). 
Gross and microscopic pathology of valves that have 
undergone spontaneous degeneration ranges from simple 
tears at the commissures (36) and isolated cusp perfora-
t ion (37) to variable degrees of surface and full thickness 
calcification (28, 31-35). Histology of the porcine bio-
prosthesis has been extensively studied before implanta-
t ion and at various periods after it has been removed 
(38). Before implantation, but after processing, endothe-
l ium and acid mucopolysaccharides are lost. Less than 
two months after implantation there is insudation of 
plasma proteins, formation of a surface layer of f ibr in, 
and deposition of macrophages, giant cells, and plate-
lets. Late changes consist of progressive disruption of 
collagen, erosion of valve surfaces, formation of platelet 
aggregates, and accumulation of l ipid. Progressive break-
down of collagen ultimately leads to tissue failure (38-
40). However, this report of collagen breakdown has not 
been conf irmed by others (41) and is not consistent with 
the persistent satisfactory funct ioning of the valve which 
occurs in most patients for up to nine years. An immuno-
logic reaction has not been shown to be associated with 
degeneration like that which occurs with formal in-
treated porcine bioprostheses (10). 
Overall valve survival wi thout degeneration (Fig. 1) at 
six, seven, and eight years has improved since our 1980 
report (19). As more valves have been evaluated, the 
standard errors have become smaller. The leading edge 
of a clinical life table does not provide an accurate inter-
pretation of events, since the large standard errors make 
this information unreliable (42). We expect our nine-
l i e 
Porc ine Bioprosthetic Heart Valves 
year data (SE of 3.4%) to be fairly accurate, but the ten-
year data with 16 patients (SE of 6.5%) may overestimate 
the incidence of degeneration. 
As in 1980, we found no significant difference in the 
incidence of degeneration between men and women, 
between the aortic or mitral posit ion, or between valves 
rinsed in antibiotic solution or not so treated. 
The incidence of degeneration is greater in younger 
patients. Al though our calculations suggest that the age 
dividing line for durabil i ty might be 20 years, this could 
not be shown statistically. As in the 1980 report, statisti-
cally significant differences occurred between patients 
under 35 years old and those over 35 years old (p= .005). 
If the dividing age is fall ing, statistical significance 
requires study of a larger number of young patients. 
In 1980, response to our report of 23 cases of valve 
degeneration (19) varied from disbelief at the low inci-
dence to the prediction that primary valve failure would 
inevitably occur within ten years for all glutaraldehyde-
treated bioprostheses. Asthe experience increases in all 
large series, the incidence of degeneration in the past 
two years has been less than predicted in 1980. To 
explain this decrease, we f ind only that the 1974 cohort 
of valves had a seven-year survival of 95% compared to 
88% and 83% for 1972 and 1973, respectively. Increased 
experience suggests that valves produced in 1974 were 
more durable than those of 1972 and 1973. 
The fact remains that in 1982 we are removing far fewer 
porcine bioprosthetic valves for degeneration than was 
predicted in early 1980. 
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